Financial Data and Key Metrics Changes - In Q4 2025, revenues grew 17% and EBITDA grew 29% year-over-year in US dollars [4] - For the full year, revenues increased nearly 10% and EBITDA grew 19% [4] - Annual EBITDA surpassed $2 billion with margins expanding to 45.7% [4][8] - Group revenue reached $4.4 billion in 2025, growing 9.9% in US dollar terms [16] - EBITDA for the year reached $2.01 billion, representing 18.8% growth [16] Business Line Data and Key Metrics Changes - Digital services revenue grew 84% year-over-year in Q4 and over 62% for the full year [4] - Digital revenues reached $759 million, representing 17% of group revenues for the full year [9][16] - EBITDA from digital services reached $207 million with an EBITDA margin of 27.3% [5] - Telecom and infrastructure revenues grew 3% despite the consolidation of TNS Plus, Deodar, and Kyrgyzstan [8] Market Data and Key Metrics Changes - Growth across markets remains balanced, with strong momentum in Pakistan, Ukraine, and Kazakhstan [10] - Bangladesh returned to positive growth during the year, while Uzbekistan continues to expand steadily [10] - Monthly active users in Pakistan's financial services business reached 21.5 million, with transaction value reaching $53 billion [11] Company Strategy and Development Direction - The company is focused on executing an asset-light strategy, having completed the sale of its Pakistan tower portfolio [5] - The listing of Kyivstar on Nasdaq was highlighted as a significant achievement [7] - The company aims to continue annual share buybacks of at least $100 million, reflecting confidence in long-term cash generation capacity [18] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth potential in both telecommunications and digital services [18] - The company expects revenue growth of 9%-12% and EBITDA growth of 7%-10% for 2026 [18] - Management acknowledged the impact of inflation and pricing power in their markets [104] Other Important Information - The company is actively pursuing digital banking licenses across its markets, including Pakistan [88] - The acquisition of TPL Insurance is expected to enhance embedded insurance offerings through JazzCash [84] - The company is developing local language large models for AI applications in its markets [95] Q&A Session Summary Question: Inquiry about the Pakistan spectrum auction and 5G network aspirations - Management highlighted the successful spectrum auction in Pakistan and the potential for both 4G and 5G network improvements [24][25] Question: Revenue growth drivers and pricing versus volume - Management attributed revenue growth to a shift towards meaningful digital services and multi-play customer relationships [32][33] Question: Future digital revenue growth and margin profile - Management indicated a balanced model for cash flow generation between telecom and digital services, with a current digital margin of 27.3% [35] Question: Capital allocation and mid-term strategy - Management emphasized a disciplined approach to capital allocation, focusing on share buybacks and strategic acquisitions [46][50] Question: Ukraine market potential and future projections - Management expressed confidence in Ukraine's long-term growth potential post-conflict, highlighting digital service opportunities [62][63] Question: Settlement with Dhabi Group and implications - Management explained the rationale behind settling with Dhabi Group to eliminate distractions and enhance investor relations [67][76] Question: Embedded insurance strategy and digital banking licenses - Management discussed the integration of insurance products into existing platforms and the pursuit of digital banking licenses [84][88]

Financial Data and Key Metrics Changes - Revenues for 2025 increased by 3.8% year-over-year to $1.033 billion, up from $995.6 million in 2024 [10][23] - Operating income for 2025 was $45.5 million, a significant improvement from an operating loss of $68.8 million in 2024, positively impacted by an $81.7 million gain from the sale of the property management division [10][24] - Adjusted EBITDA improved to a loss of $14 million in 2025, compared to a loss of $24.1 million in 2024 [10][25] - Net income for 2025 was $15.2 million or $0.17 per diluted share, compared to a net loss of $76.3 million or ($0.91) per diluted share in 2024 [24] Business Line Data and Key Metrics Changes - Revenues from the development marketing division increased by $12.6 million from the prior year, totaling $80.4 million in 2025, up from $67.8 million in 2024 [14][17] - The average price per transaction in 2025 increased to $1.86 million per home sold, compared to $1.67 million in 2024 [15] - The number of homes sold priced over $5 million increased by 25% in 2025, with 1,282 such homes sold [16] Market Data and Key Metrics Changes - The Northeast market led revenue increases, with a rise of $17.5 million or 9.2% from 2024 [17] - Total brokerage cash receipts in January and February 2026 were 12.4% lower than the same period in 2025 [18] Company Strategy and Development Direction - The company is focused on expanding its footprint in existing markets and entering new high-potential regions, including recent expansions into the French Alps and other luxury destinations [5][6] - Two growth teams have been launched to support market expansion and agent recruitment [6][7] - The company has reinforced its leadership team to drive growth and innovation, including new appointments in key strategic roles [8][9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's positive momentum and competitive advantage due to a strong balance sheet [13] - The company anticipates that 2026 will mark the beginning of a new growth phase as investments made in 2025 begin to yield results [11][20] - Management acknowledged ongoing economic pressures, including geopolitical uncertainties and elevated mortgage rates, but remains optimistic about future opportunities [18] Other Important Information - The company maintained cash and cash equivalents of approximately $115.5 million at December 31, 2025, with no long-term debt [11][26] - The company has made significant investments in market intelligence, technology, and agent resources to enhance service offerings [9] Q&A Session Summary - No specific questions or answers were provided in the content regarding the Q&A session. The call concluded without a detailed Q&A segment [28]

Financial Data and Key Metrics Changes - The company ended 2025 with cash totaling $7.6 million, an increase from $3.7 million as of December 31, 2024 [14] - The net loss for Q4 2025 was $1.6 million, or $0.73 per diluted share, compared to a net loss of $2.8 million, or $3.29 per diluted share for Q4 2024 [18] - For the full year 2025, the net loss was $8 million, or $5.32 per diluted share, down from a net loss of $14.1 million, or $17.45 per share in 2024 [18] Business Line Data and Key Metrics Changes - Research and development expenses for Q4 2025 were $0.3 million, down from $0.8 million in Q4 2024, primarily due to decreased manufacturing and consulting costs [15] - For the full year 2025, R&D expenses were $1.8 million, a significant decrease from $5.4 million in 2024, attributed to lower manufacturing and consulting costs [16] - General and administrative expenses for Q4 2025 were $1.3 million, down from $2 million in Q4 2024, mainly due to reduced compensation and professional fees [16] Market Data and Key Metrics Changes - The company is focusing on the recurrent CDI market, which affects approximately 500,000 patients annually in the U.S., resulting in about 30,000 deaths and a public health cost burden of approximately $5 billion [21] Company Strategy and Development Direction - The company is launching a new clinical trial program for ibezapolstat in patients with recurrent CDI, aiming to shift treatment from two agents to one [9] - The company plans to request FDA approval for ibezapolstat under the Limited Population Pathway for Antibacterial and Antifungal Drugs guidance [10] - The company is pursuing funding opportunities for its phase 3 clinical trial programs and considering alternative financial pathways [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating the challenging macroeconomic environment and industry sector while continuing to develop ibezapolstat's competitive profile [13] - The FDA's potential shift to a one-trial requirement for registration is seen as a positive development that could benefit the company's clinical development programs [11] Other Important Information - The company received a new patent for its Pol IIIC inhibitors, extending to December 2039, which covers composition of matter and method of use [11] - The company has approximately $7 million to $8 million left on its equity line of credit, which may support ongoing clinical trials [40] Q&A Session Summary Question: What is the primary endpoint for the recurrent CDI trial and its cost? - The primary endpoint is prevention of recurrence, with an evaluation period of eight weeks, and the trial cost is estimated to be between $4 million and $5 million [27][36] Question: When will the pilot study for recurrent CDI start and conclude? - Enrollment is expected to start in the second half of 2026, with full enrollment anticipated in 12-15 months [37] Question: How many patients are projected for the phase 3 trial for recurrent CDI? - The current projection is between 360 and 400 patients for a single trial in the recurrent CDI indication [42] Question: Is U.S.-based manufacturing a focus for the company? - Yes, the company is in discussions with government agencies regarding U.S.-based manufacturing, which is important for potential funding [46] Question: How real is the FDA's one-trial requirement? - Management is optimistic about the one-trial requirement being formalized, which could change the clinical trial landscape [73]

Financial Data and Key Metrics Changes - Fourth quarter net revenues reached RMB 1.14 billion, up 40.3% year-over-year, while total net revenues for the full year grew 44% to RMB 3.96 billion [14] - Gross margin expanded to 31.4% in the fourth quarter, up from 27% a year ago, and for the full year, gross margin increased to 29.9% [14][15] - Non-GAAP operating income doubled to RMB 570 million for the full year, with non-GAAP net income surging to RMB 1.16 billion [15] Business Line Data and Key Metrics Changes - International sales constituted 76.5% of fourth quarter revenue, marking a significant milestone in the company's global expansion [6] - Domestic revenue in mainland China grew by over 20% compared to the previous year, driven by stricter customs enforcement [10][28] Market Data and Key Metrics Changes - The Asia Pacific region showed strong market growth, with the company capturing over 20% of the specialty store channel in East Asia [7] - The U.K. market experienced a contraction in total retail value, but the company managed to grow its revenue by acquiring new customers and expanding shelf space [26] Company Strategy and Development Direction - The company is focusing on a consumer-first strategy and effective execution to lead the global smokeless transition [5] - European expansion is a top strategic priority, with investments in local distribution and partnerships with retail giants [9] - The company is integrating AI into its operations to enhance efficiency and predict consumer preferences [11][12] Management's Comments on Operating Environment and Future Outlook - Management expects a stable and predictable environment for international business in 2026, projecting double-digit growth for the broader industry [20] - The company views its strong cash position as a strategic asset, allowing for disciplined M&A and investments while maintaining shareholder returns [22] Other Important Information - The company ended 2025 with total financial assets of RMB 15.73 billion (approximately $2.2 billion), providing financial flexibility for strategic initiatives [16] - The company has returned over $500 million to shareholders through dividends and share repurchases [16] Q&A Session Summary Question: What is the growth outlook for overseas markets and strategies for expansion? - Management expects significant growth in overseas markets, projecting to grow faster than the industry average, with a strong pipeline of international markets for 2026 [20] Question: Can you provide an update on European operations and guidance for 2026? - European operations have shown resilience despite market contractions, with a positive outlook for 2026 as the industry consolidates around compliant brands [26][28] Question: How does management view consumer demand sensitivity across international markets? - Management believes demand remains resilient as products are embedded in daily routines, and the company is insulated from energy and freight volatility [38] Question: What is the current progress of nicotine pouch products? - The company has started rollouts of modern oral products in Europe, with positive feedback from consumers and plans for channel expansion in 2026 [40]

Financial Data and Key Metrics Changes - Revenues for 2025 increased by 3.8% year-over-year to $1.033 billion, up from $995.6 million in 2024 [9][21] - Operating income for 2025 was $45.5 million, a significant improvement from an operating loss of $68.8 million in 2024 [9] - Adjusted EBITDA for 2025 improved to a loss of $14 million, compared to a loss of $24.1 million in 2024 [22] - Net income for 2025 was $15.2 million or $0.17 per diluted share, compared to a net loss of $76.3 million or ($0.91) per diluted share in 2024 [21] Business Line Data and Key Metrics Changes - Revenues from the development marketing division increased to $80.4 million in 2025, up from $67.8 million in 2024, benefiting from investments made in recent years [15] - The average price per transaction in 2025 increased to $1.86 million per home sold, compared to $1.67 million in 2024 [13] - The development marketing division's active project pipeline totals $25.3 billion in gross transaction value, with $17.5 billion in Florida alone [15] Market Data and Key Metrics Changes - The Northeast market led revenue increases, with a rise of $17.5 million or 9.2% from 2024 [15] - In the fourth quarter of 2025, agents sold 282 homes priced at more than $5 million, representing 5.4% of total transactions, and 1,282 such homes during the year, a 25% increase from 2024 [14] Company Strategy and Development Direction - The company aims to deepen its footprint in existing markets while entering new high-potential regions, including recent expansions into the French Alps and other luxury destinations [5][6] - Two growth teams have been launched: one focused on expanding within current markets and another on new market entries [6] - The company has reinforced its leadership team to drive growth and innovation, including the appointment of a Chief Strategy Officer and a Chief Technology Officer [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's positive momentum and competitive advantage due to a strong balance sheet, which allows for growth in existing and new markets [12] - The company anticipates that 2026 will mark the beginning of a new growth phase as investments made in 2025 begin to yield results [10] - Management acknowledged ongoing economic pressures, including geopolitical uncertainties and elevated mortgage rates, but remains optimistic about future performance [16] Other Important Information - The company had cash and cash equivalents of approximately $115.5 million at December 31, 2025, with no long-term debt following the redemption of convertible notes [10][23] - The company has made significant investments in market intelligence, technology, and agent resources to enhance service offerings [8] Q&A Session Summary - No specific questions or answers were provided in the content regarding the Q&A session.

Financial Data and Key Metrics Changes - In Q4 2025, revenues grew 17% and EBITDA grew 29% year-over-year in US dollars. For the full year, revenues increased nearly 10% and EBITDA grew 19% [3][14] - Group revenue reached $4.4 billion in 2025, growing 9.9% in US dollar terms, with an adjusted growth of around 11% in dollars and over 15% in local currency terms [6][14] - EBITDA for the year reached $2.01 billion, representing 18.8% growth, with an EBITDA margin expanding to 45.7% [14][15] Business Line Data and Key Metrics Changes - Digital services revenue grew 84% year-over-year in Q4 and over 62% for the full year, now representing more than 17% of group revenue [4][6] - Digital revenues reached $759 million for the full year, contributing significantly to profitability with an EBITDA margin of 27.3% [4][14] - Telecom and infrastructure revenues grew 3%, supported by average revenue per user growth driven by strong subscriber engagement [6] Market Data and Key Metrics Changes - Growth across markets remains balanced, with strong momentum in Pakistan, Ukraine, and Kazakhstan, while Bangladesh returned to positive growth [9] - Financial services in Pakistan performed strongly, with monthly active users reaching 21.5 million and transaction value reaching $53 billion, equivalent to around 13% of Pakistan's GDP [10] - The company serves over 135 million active digital service users, with total transaction value across the ecosystem reaching $55 billion, growing more than 50% year-over-year [10] Company Strategy and Development Direction - The company executed an asset-light strategy, completing the sale of its Pakistan tower portfolio and launching direct-to-cell connectivity with Starlink [4][5] - The listing of Kyivstar on Nasdaq was highlighted as a significant achievement, with plans for continued share buybacks of at least $100 million annually [5][16] - The company aims to balance its digital and telecom services, with a long-term goal of achieving a 50-50 revenue split between the two segments [116] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth of both core telecommunications and digital services businesses, expecting revenue growth of 9%-12% and EBITDA growth of 7%-10% for 2026 [16] - The company noted that pricing control remains strong, allowing it to implement fair value pricing and gain wallet share from customers [7] - Management emphasized the importance of investing in infrastructure to support digital services, particularly in markets with significant growth potential [122] Other Important Information - The company is actively pursuing digital banking licenses in its markets, particularly in Pakistan, to enhance its financial services offerings [89] - The acquisition of TPL Insurance is expected to enhance the company's embedded insurance offerings, leveraging its existing customer base [84] - The company is developing local language large models for AI applications, positioning itself uniquely in its markets [95] Q&A Session Summary Question: Regarding the Pakistan spectrum auction and 5G network aspirations - Management highlighted the successful acquisition of 190 megahertz of spectrum for $240 million, indicating plans to improve 4G services while also deploying 5G where relevant [20][23] Question: Insights on revenue growth drivers - Management attributed growth to a shift from selling raw data to providing meaningful digital services, enhancing customer relationships and reducing churn [31][32] Question: Plans for 2027 bonds and capital allocation - Management confirmed plans to address the 2027 bonds this year and emphasized a disciplined approach to capital allocation, focusing on accretive investments [110][112] Question: Future of the digital financial ecosystem in Pakistan - Management expressed optimism about upgrading to a full digital banking license, which would unlock new growth opportunities in Pakistan's financial services market [127]

Financial Data and Key Metrics Changes - The company ended 2025 with cash totaling $7.6 million, an increase from $3.7 million as of December 31, 2024 [12] - The net loss for Q4 2025 was $1.6 million, or $0.73 per diluted share, compared to a net loss of $2.8 million, or $3.29 per diluted share for Q4 2024 [16] - For the full year 2025, the net loss was $8 million, or $5.32 per diluted share, down from a net loss of $14.1 million, or $17.45 per share in 2024 [16] Business Line Data and Key Metrics Changes - Research and development expenses for Q4 2025 were $0.3 million, down from $0.8 million in Q4 2024, primarily due to decreased manufacturing and consulting costs [13] - For the full year 2025, R&D expenses totaled $1.8 million, a significant decrease from $5.4 million in 2024, attributed to lower manufacturing and consulting costs [14] - General and administrative expenses for Q4 2025 were $1.3 million, down from $2 million in Q4 2024, mainly due to reduced compensation-related costs and professional fees [14] Market Data and Key Metrics Changes - The company presented at IDWeek in Atlanta, highlighting the potential of ibezapolstat and its microbiome-sparing properties, which could position it favorably in the market [4][5] - The FDA's recent announcement regarding a one-trial requirement for registration could significantly impact the company's clinical development programs and market entry strategy [10] Company Strategy and Development Direction - The company is launching a new clinical trial program for ibezapolstat in patients with recurrent CDI, aiming to shift treatment paradigms from two agents to one [7][19] - The company is pursuing funding opportunities for its phase 3 clinical trial programs and exploring alternative financial pathways [11] - The focus on U.S.-based manufacturing aligns with government interests in public-private partnerships, potentially enhancing funding opportunities [41] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating the macroeconomic challenges and emphasized the competitive profile of ibezapolstat [12] - The potential for ibezapolstat to be the first agent to demonstrate clinical success in both treating and preventing recurrent CDI was highlighted as a significant opportunity [19] - The company is optimistic about the implications of the FDA's new guidance on clinical trial requirements for its development programs [10] Other Important Information - The company received a new patent for its Pol IIIC inhibitors, extending protection to December 2039 [10] - The clinical program for ibezapolstat has received fast track designations from the FDA, enhancing its development prospects [11] Q&A Session Summary Question: What is the primary endpoint for the recurrent CDI trial and its cost? - The primary endpoint is prevention of recurrence, with an evaluation period of eight weeks and a trial cost estimated between $4 million and $5 million [22][32] Question: When will the pilot study start and conclude? - Enrollment for the pilot study is expected to begin in the second half of 2026, with full enrollment anticipated to take 12-15 months [33] Question: How many patients will be needed for the phase 3 trial? - The current projection for the phase 3 trial in recurrent CDI is between 360 and 400 patients, depending on data from the open-label trial [37] Question: Is U.S.-based manufacturing a focus for the company? - Yes, the company is engaging with government agencies regarding U.S.-based manufacturing, which is seen as beneficial for securing funding [41]

Financial Data and Key Metrics Changes - Total revenue for 2025 increased by 16% year-over-year to $469.5 million, with net income improving to $41.9 million and adjusted EBITDA increasing approximately threefold to $56 million [4][5] - Operating cash flow rose by 23% to $81.1 million, driven by improving power market conditions [4] - For Q4 2025, electric sales increased by 3% to $71.6 million, while coal sales rose by 24% to $29.1 million [13][14] - Total operating revenue for Q4 increased by 8% to $102.4 million, with a net loss of $0.2 million compared to a net loss of $215.8 million in the prior year [14][15] Business Line Data and Key Metrics Changes - Electric sales were the primary driver of revenue growth, increasing approximately 19% to $310.7 million for the full year [4] - Coal sales increased by 8% year-over-year to $148.7 million, supported by both internal fuel needs and third-party customers [5] - In Q4, coal sales growth was driven by higher third-party shipments, reflecting production optimization at Sunrise Coal [14] Market Data and Key Metrics Changes - The MISO region is experiencing strong demand for reliable dispatchable generation, tightening supply conditions and increasing the value of accredited capacity [6][7] - The company has made progress in selling energy and capacity at elevated prices, with competitive offers for accredited capacity over a decade in length [7] Company Strategy and Development Direction - The company is advancing its transformation into a vertically integrated independent power producer, focusing on maintaining operational reliability and executing strategic initiatives for long-term growth [4][9] - Plans to add up to 515 MW of natural gas generation under the ERAS program, targeting completion around Q3 2029, leveraging existing infrastructure at the Merom site [8][9] - The company aims to maintain a disciplined approach to capital allocation, with capital expenditures expected to increase modestly in 2026 compared to 2025 [9][17] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the current market conditions, noting increased interest and pricing pressure for long-term power purchase agreements (PPAs) [22][23] - Operational challenges at the Merom power plant were acknowledged, with planned maintenance expected to improve performance ahead of peak summer demand [5][26] - The company is actively negotiating with multiple counterparties for equipment and PPAs to support the gas expansion project [31][32] Other Important Information - The company completed a $25 million prepaid energy forward sales contract and raised approximately $14 million through an ATM offering [17] - A new $120 million senior secured credit facility was established to support general corporate purposes and potential equipment deposits for the gas generation expansion [18] Q&A Session Summary Question: What are the main gating items for long-term PPA opportunities? - Management indicated that multiple parties are involved in negotiations, with increasing interest and pricing pressure in the market [22][23] Question: Can you provide details on the operational issues at Merom? - Management noted equipment failures affecting performance, with a planned major maintenance outage expected to improve reliability [25][26] Question: What factors will determine the completion date for the natural gas expansion? - Key factors include securing equipment in a timely manner and aligning long-term PPAs to support the project [31][32] Question: How will recent EPA decisions impact the business? - Most plants, including Merom, are already MACT compliant, and while ongoing costs exist, the changes may ease operational burdens [34] Question: Will long-term PPAs be announced in several tranches? - Management expects to announce multiple tranches rather than a single large deal [37] Question: What is the outlook for capital expenditures in 2026? - Capital expenditures are expected to be modestly higher than 2025 levels, excluding ERAS developments [44]

Financial Data and Key Metrics Changes - Fiscal 2026 first quarter revenue totaled $278.6 million, down 17% from the prior year, driven by a 30% decrease in pricing due to higher industry supply [17] - Despite lower revenue, gross profit remained consistent at $31.6 million, leading to a gross margin increase of 190 basis points to 11.3% compared to the same period last year [17][18] - Adjusted EBITDA increased 5% to $18.5 million compared to $17.7 million last year, driven by higher avocado volume sold and improved per unit margins [21] Business Line Data and Key Metrics Changes - Marketing and Distribution segment net sales decreased 21% to $234.8 million, but adjusted EBITDA increased 33% to $12.9 million, reflecting higher avocado volume sold and solid per unit margins [21] - International Farming segment total sales increased 15% to $10.6 million, with adjusted EBITDA rising 28% to $2.3 million due to improved pack house utilization [22] - Blueberry segment total sales increased 12% to $40.8 million, but adjusted EBITDA decreased to $3.3 million due to lower per acre yields [23] Market Data and Key Metrics Changes - Mexican supply was abundant this quarter, with higher yields in the current harvest season compared to last year, contributing to a 14% growth in avocado volumes [6][17] - Household penetration of avocados reached approximately 72%, with per capita consumption nearly tripling over the past two decades, indicating strong demand trends [8] Company Strategy and Development Direction - The company is focused on leveraging the Calavo acquisition to enhance its core avocado business and expand into prepared foods, which is seen as a strategic opportunity [10][12] - Integration planning for the Calavo acquisition is underway, with expectations of achieving at least $25 million in annualized cost synergies within 18 months of closing [14] - The company aims to balance reinvestment in the business with returning capital to shareholders as free cash flow ramps up [15][49] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the underlying strength of the business model despite near-term pricing pressures, emphasizing the long-term growth potential in avocado consumption [28] - The company anticipates a lower pricing environment in the second quarter, with expected avocado industry volumes increasing by approximately 10%-15% [25][26] - Management highlighted the importance of maximizing productivity and strengthening customer partnerships to drive long-term value creation [28] Other Important Information - SG&A expenses increased by $6.9 million, or 31%, primarily due to transaction advisory costs associated with the Calavo acquisition [18] - Cash and cash equivalents were $44.8 million as of January 31, 2026, down from $64.8 million as of October 31, 2025 [24] Q&A Session Summary Question: Insights on Calavo acquisition and synergy realization - Management feels confident about the $25 million synergy estimate and sees opportunities for further upside, focusing on cost-related synergies and growth potential [31][33] Question: Impact of pricing environment on margins - Management acknowledged that while lower prices compress margins, the focus remains on maintaining profitability through volume and per unit margins [39][41] Question: Timeline for blueberry farms reaching full productivity - Management expects blueberry farms to reach full productivity within 12-18 months, with improved yields anticipated as the plants mature [45][47] Question: Long-term capital allocation strategy - Management is committed to balancing debt management, reinvestment in growth, and returning capital to shareholders, with discussions ongoing about shareholder returns [49][51]

Financial Data and Key Metrics Changes - Consolidated operating income was approximately $800 thousand in Q4 2025, down from $1.5 million in Q4 2024, impacted by $400 thousand in M&A-related expenses [7] - Revenue increased to $11.9 million in Q4 2025 from $10.8 million in Q4 2024 [10] - Adjusted EBITDA decreased to $1.1 million in Q4 2025 from $2.1 million in the prior year [10] - Net income was approximately $300 thousand or $0.01 per diluted share in Q4 2025, compared to a loss of approximately $200 thousand or $0.01 per diluted share in Q4 2024 [10] Business Line Data and Key Metrics Changes - The industrial assets division reported operating income of approximately $1.1 million in Q4 2025, up from approximately $800 thousand in the prior year [7] - The financial assets division reported operating income of approximately $900 thousand in Q4 2025, down from $1.9 million in the prior year [7] - ALT, a part of the industrial assets division, reported operating income of $538 thousand in Q4 2025, compared to $276 thousand in the prior year [8] Market Data and Key Metrics Changes - Consumer loan delinquencies remain elevated, particularly in credit card and auto loans, which are expected to lead to increased charge-offs moving forward [9] - The company anticipates a significant amount of loans in the commercial real estate (CRE) market will be released due to ongoing pressures [5][21] Company Strategy and Development Direction - The company aims to define 2026 as the "year of the needle mover," focusing on larger transactions and aggressive M&A activities [5] - The recent acquisition of DebtX is expected to enhance capabilities in the financial asset segment and is projected to be accretive in 2026 [10][18] - The company has moved into a new facility designed to accelerate growth and increase operational efficiency [9] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about 2026, indicating a shift from a cautious approach to more aggressive transaction activity as companies are expected to release assets [3][4] - There is a belief that the current economic environment will lead to increased activity in auctions and larger transactions as companies move past a "wait and see" mentality [27] Other Important Information - The company has a strong balance sheet with stockholders' equity of $67 million as of December 31, 2025, and a cash balance of $20.5 million [11] - The company plans to resume share repurchases after authorizing a new program for up to $7.5 million [12] Q&A Session Summary Question: Clarification on DebtX acquisition accretion - The company expects the DebtX acquisition to be accretive on both operating income and net income basis [18] Question: Seasonality of DebtX business - DebtX typically has a strong Q4, with over 50% of their revenue often generated in that quarter [19] Question: Exposure to private credit market - The DebtX acquisition provides exposure to the private credit market, particularly in relation to loans struggling to be refinanced [21] Question: Larger transactions in 2026 - Management noted a general hesitation in 2025 due to geopolitical and macroeconomic factors, but signs indicate a return to larger transactions in 2026 [26][27] Question: Specialty lending performance - The modestly negative performance in specialty lending was attributed to a lack of funding and the need to increase loan amounts in 2026 [32]